dc.contributor.author |
Illouz, Tomer |
dc.contributor.author |
Biragyn, Arya |
dc.contributor.author |
Iulita, Maria Florencia |
dc.contributor.author |
Flores-Aguilar, Lisi |
dc.contributor.author |
Dierssen, Mara |
dc.contributor.author |
De Toma, Ilario |
dc.contributor.author |
Antonarakis, Stylianos E. |
dc.contributor.author |
Yu, Eugene |
dc.contributor.author |
Herault, Yann |
dc.contributor.author |
Potier, Marie-Claude |
dc.contributor.author |
Botté, Alexandra |
dc.contributor.author |
Roper, Randall |
dc.contributor.author |
Sredni, Benjamin |
dc.contributor.author |
London, Jacqueline |
dc.contributor.author |
Mobley, William |
dc.contributor.author |
Strydom, Andre |
dc.contributor.author |
Okun, Eitan |
dc.date.accessioned |
2021-11-30T07:17:02Z |
dc.date.available |
2021-11-30T07:17:02Z |
dc.date.issued |
2021 |
dc.identifier.citation |
Illouz T, Biragyn A, Iulita MF, Flores-Aguilar L, Dierssen M, De Toma I, Antonarakis SE, Yu E, Herault Y, Potier MC, Botté A, Roper R, Sredni B, London J, Mobley W, Strydom A, Okun E. Immune dysregulation and the increased risk of complications and mortality following respiratory tract infections in adults with Down dyndrome. Front Immunol. 2021;12:621440. DOI: 10.3389/fimmu.2021.621440 |
dc.identifier.issn |
1664-3224 |
dc.identifier.uri |
http://hdl.handle.net/10230/49092 |
dc.description.abstract |
The risk of severe outcomes following respiratory tract infections is significantly increased in individuals over 60 years, especially in those with chronic medical conditions, i.e., hypertension, diabetes, cardiovascular disease, dementia, chronic respiratory disease, and cancer. Down Syndrome (DS), the most prevalent intellectual disability, is caused by trisomy-21 in ~1:750 live births worldwide. Over the past few decades, a substantial body of evidence has accumulated, pointing at the occurrence of alterations, impairments, and subsequently dysfunction of the various components of the immune system in individuals with DS. This associates with increased vulnerability to respiratory tract infections in this population, such as the influenza virus, respiratory syncytial virus, SARS-CoV-2 (COVID-19), and bacterial pneumonias. To emphasize this link, here we comprehensively review the immunobiology of DS and its contribution to higher susceptibility to severe illness and mortality from respiratory tract infections. |
dc.format.mimetype |
application/pdf |
dc.language.iso |
eng |
dc.publisher |
Frontiers |
dc.relation.ispartof |
Front Immunol. 2021;12:621440 |
dc.rights |
© 2021 Illouz, Biragyn, Iulita, Flores-Aguilar, Dierssen, De Toma, Antonarakis, Yu, Herault, Potier, Botté, Roper, Sredni, London, Mobley, Strydom and Okun. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
dc.rights.uri |
http://creativecommons.org/licenses/by/4.0/ |
dc.title |
Immune dysregulation and the increased risk of complications and mortality following respiratory tract infections in adults with Down dyndrome |
dc.type |
info:eu-repo/semantics/article |
dc.identifier.doi |
http://dx.doi.org/10.3389/fimmu.2021.621440 |
dc.subject.keyword |
COVID-19 |
dc.subject.keyword |
Down syndrome |
dc.subject.keyword |
Hospitalization |
dc.subject.keyword |
Immune dysregulation |
dc.subject.keyword |
Interferon |
dc.subject.keyword |
Respiratory tract infections |
dc.rights.accessRights |
info:eu-repo/semantics/openAccess |
dc.type.version |
info:eu-repo/semantics/publishedVersion |